Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1604 • 2018 ACR/ARHP Annual Meeting
Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime¹, Ilja Tchetverikov², Andreas H. Gerards³, M.R. Kok⁴, Cathelijne W. Y. Appels⁵, Wiebo L. van der Graaff⁶, Johannes H. L. M. van Groenendael⁷, Lindy-Anne Korswagen³, Josien J Veris-van Dieren⁸, JMW Hazes¹ and Marijn Vis¹, ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ⁴Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁵Rheumatology, Amphia Hospital, Breda, Netherlands, ⁶Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁷Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: From previous cross-sectional research we know that minimal disease activity (MDA) is associated with better health-related quality of life (HRQoL) in psoriatic arthritis (PsA).…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Curtis Sobchak¹, Shadi Akhtari², Paula Harvey², Dafna D Gladman³, Vinod Chandran⁴, Richard J. Cook⁵ and Lihi Eder⁶, ¹Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 1637 • 2018 ACR/ARHP Annual Meeting
Serious Infections Among Psoriatic Arthritis Patients Taking TNF Inhibitors Versus Non-TNF Biologics: A Systematic Review and Network Meta-Analysis
Saad Ullah Malik¹, Kinza Muzaffar², Jawad Bilal³, Warda Faridi⁴ and Salman Muddassir⁵, ¹University of Arizona, Tucson, AZ, ²Internal medicine, Oak Hill Hospital,affiliated with USF, spring hill, FL, ³Internal Medicine, University of Arizona, Tucson, AZ, ⁴Department of Hematology/Oncology, University of Arizona, Tucson, AZ, ⁵Oakhill Hospital, Brookesville, FL
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory condition of peripheral joints. If left untreated, it can lead to significant pain and joint deformity. Its treatment…
Abstract Number: 1972 • 2018 ACR/ARHP Annual Meeting
Resolving the Synovial Fluid Proteome and Peptidome for Disease-Specific Mediators of Inflammatory Arthritis
Shalini Mahendran¹, Eleftherios Diamandis² and Vinod Chandran³, ¹Laboratory Medicine and Pathobiology, University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ²Pathology and Laboratory Medicine, University of Toronto, Mount Sinai Hospital, University Health Network, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Idiopathic inflammatory arthritis (IA) is a T-cell driven chronic condition characterized an imbalance in cell proliferation and apoptosis leading to significant synovial hyperplasia and…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 2135 • 2018 ACR/ARHP Annual Meeting
Identification of Psoriatic Arthritis Using an Administrative Claims-Based Algorithm
Julia Ford¹, Lindsey A. MacFarlane¹, Angela Tong² and Seoyoung C. Kim^1,3, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that can present variably in patients with or without psoriasis. The ability to accurately identify PsA…
Abstract Number: 231 • 2018 ACR/ARHP Annual Meeting
Rates of Influenza Vaccination in a Cohort of Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Andreea Coca¹, James Dolan² and Christopher T. Ritchlin², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: The infections complicating rheumatic diseases cause significant morbidity and mortality. Rheumatoid arthritis and psoriatic arthritis patients are at increased risk of infection due to…
Abstract Number: 2164 • 2018 ACR/ARHP Annual Meeting
IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases
Mégane Beurai-Weber Jr.¹, Audrey Jaussent², Guilhem du Cailar³, Marie-Christine Picot², François Roubille Sr.⁴, Jean-David Cohen⁵, Jacques Morel⁶, Jean Bousquet⁷, Pierre Fesler⁸, Bernard Combe⁹ and Claire Daien¹⁰, ¹Rheumatology Department, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ²Department of medical information, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University, MONTPELLIER, France, ⁵IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ⁸Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁹University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, ¹⁰Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France
Background/Purpose: EULAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic…
Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Enrique R Soriano¹, Hugo Madariaga², Oswaldo Castañeda³, Gustavo Citera⁴, Emilce E Schneeberger⁴, Mario H Cardiel⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Harry Shi⁶ and Dario Ponce de Leon⁸, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Clínica del Sur, Arequipa, Peru, ³Clínica Anglo Americana, Lima, Peru, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Lima, Peru
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
Abstract Number: 685 • 2018 ACR/ARHP Annual Meeting
Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
William FC Rigby¹, Gerd R. Burmester², Oliver FitzGerald³, Valderilio F Azevedo⁴, Peter Nash⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Cunshan Wang⁷ and Thomas Jones⁶, ¹Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Charité – University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology, St Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College, Dublin, Ireland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵University of Queensland, Brisbane, Australia, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA). In most countries where tofacitinib is…
Abstract Number: 2568 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Philip J. Mease¹, Arthur Kavanaugh², Andreas Reimold³, Hasan Tahir⁴, Juergen Rech⁵, Stephen Hall⁶, Piet Geusens⁷, Pellet Pascale⁸, Evie Maria Delicha⁹, Luminita Pricop¹⁰ and Shephard Mpofu⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Monash University,, Melbourne, Australia, ⁷University of Hasselt, Belgium and Maastricht University Hospital, Maastricht, Netherlands, ⁸Novartis Pharma AG, basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody, provided rapid and significant improvements in all key clinical domains of psoriatic arthritis (PsA) in the…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].